Healthcare
Greybrook’s healthcare business is focused in 2 major areas where our partners have a wealth of knowledge and a track record of success: The first is bringing to market paradigm changing science based treatments or technologies.
The second is building managing and operating consumer based HealthCare companies. This includes private HealthCare clinics and service providers with particular expertise in private pay services and elective procedures.
The principals of Greybrook have spent the majority of their careers in the healthcare industry in both Canada and the U.S. and have expertise in both operations and corporate finance. In total, the principals of the firm have been directly involved at the executive management level in creating billions of dollars of enterprise value for both private and public healthcare companies.
With more than $3 billion dollars worth of corporate finance transactions in the sector, our experience and expertise in combination with our extensive cross border network of relationships provides Greybrook a unique perspective and a major advantage in this space.
TearLab Corporation
NASDAQ:TEAR, TSX:TLB
www.ocusense.com
TearLab Corporation, headquartered in San Diego, California, is commercializing a proprietary in vitro diagnostic tear testing platform, TearLab™, capable of accurately and rapidly measuring biomarkers in tears at the point-of-care.
TearLab Corporation is developing TearLab™ Osmolarity, a test intended to measure tear film osmolarity.
TearLab Corporation completed a merger with Occulogix Inc. in 2008. Occulogix Inc. went public in 2004 raising over 100 Million dollars to support its commercialization efforts.
MacuHealth
Macular Degeneration is a degenerative eye disease and the leading cause of blindness in people over the age of 50 in North America. Low Macular Pigment (MP) is a major risk factor for Macular Degeneration.
Macuhealth with LMZ3 is a patented nutritional supplement that contains the three pigments found in the macula. Regular intake of Macuhealth with LMZ3 has been shown to restore macular pigment to normal levels (up to 40% increase in MP over a 6 month period*)
The MacuScope™ is an instrument that can accurately measure MP and is essential in screening low MP patients as well as tracking ongoing restoration of MP to normal levels.
ScienceWithVision Inc.
ScienceWithVision Inc. is a Canadian medical technology organization that is focused on providing eye doctors with state-of-the-art medical technology to raise their standard of care options.
ScienceWithVision is the exclusive Canadian distributor for the Health Canada approved MacuScope™ – Canada’s first macular pigment optical density meter. This instrument allows eye doctors to identify patients at risk for Macular Degeneration and we provide sales, leasing and support for clinics across Canada. Our MacuHealth with LMZ³ supplement is a patented formulation including only the three retinal carotenoids found in the macula and is designed to re-pigment the macula and reduce patients’ risk for AMD.
MacuHealth with LMZ³ has shown up to 40% increase in Macular Pigment over 6 months* and is available only through eye doctors.
Our Management and Medical Advisory teams are industry leaders in eye care technology and are dedicated to providing the newest and most effective technologies to eye doctors across Canada.
BioTuesday.ca
One thing is crystal clear – ever since Leonard Zehr retired from The Globe and Mail, there has been a noticeable void of traditional Canadian business media coverage of all but the very largest healthcare issuers. So, we’ve created BioTuesday.ca to change that. Our goal is to give great, but not necessarily big or well known, healthcare companies and their stories the exposure that they deserve in this country.
We plan on covering as many companies as we can. If we call you for an interview, please rest assured that there are truly no strings or costs attached. There also won’t be any outside voices tearing your company apart in our blog posts. Instead, we’ve designed this to be a user-friendly chance for CEOs and other execs to sketch where they are and where they’re going.